吸入无机亚硝酸盐对射血分数保留心衰患者运动能力的影响:INDIE-HFpEF随机临床试验
该多中心、双盲、安慰剂对照交叉试验纳入105例射血分数保留的心衰(HFpEF)患者,评估吸入雾化无机亚硝酸盐4周对运动能力的影响。
要点
- 吸入无机亚硝酸盐4周未改善HFpEF患者的峰值耗氧量。
- 日常活动水平、生活质量评分、功能分级等次要终点均无显著差异。
- 亚硝酸盐组心衰恶化发生3例(2.9%),安慰剂组8例(7.6%)。
核心结论
- 在HFpEF患者中,吸入无机亚硝酸盐4周与安慰剂相比未显著改善运动能力。
研究设计与样本
- 多中心、双盲、安慰剂对照、2治疗交叉试验,纳入105例HFpEF患者,来自美国17个中心。
- 干预为经微网雾化器吸入无机亚硝酸盐或安慰剂,每阶段6周:2周基线/洗脱后,46 mg每日三次用1周,继以80 mg每日三次用3周。
- 主要终点为峰值耗氧量(mL/kg/min),治疗4周后评估。
关键数值与推荐
- 堪萨斯城心肌病问卷评分范围0-100,评分越高生活质量越好。
- 亚硝酸盐阶段心衰恶化3例(2.9%),安慰剂阶段8例(7.6%)。
临床怎么用
- 不推荐对HFpEF患者使用吸入无机亚硝酸盐以改善运动能力。
- 该干预未显示对日常活动、生活质量或功能分级有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF. OBJECTIVE: To determine the effect of 4 weeks' administration of inhaled, nebulized inorganic nitrite on exercise capacity in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled, 2-treatment, crossover trial of 105 patients with HFpEF. Participants were enrolled from July 22, 2016, to September 12, 2017, at 17 US sites, with final date of follow-up of January 2, 2018. INTERVENTIONS: Inorganic nitrite or placebo administered via micronebulizer device. During each 6-week phase of the crossover study, participants received no study drug for 2 weeks (baseline/washout) followed by study drug (nitrite or placebo) at 46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was peak oxygen consumption (mL/kg/min). Secondary end points included daily activity levels assessed by accelerometry, health status as assessed by the Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores reflecting better quality of life), functional class, cardiac filling pressures assessed by echocardiography, N-terminal fragment of the prohormone brain natriuretic peptide levels, other exercise indices, adverse events, and tolerability. Outcomes were assessed after treatment for 4 weeks. RESULTS: Among 105 patients who were randomized (median age, 68 years; 56% women), 98 (93%) completed the trial. During the nitrite phase, there was no significant difference in mean peak oxygen consumption as compared with the placebo phase (13.5 vs 13.7 mL/kg/min; difference, -0.20 [95% CI, -0.56 to 0.16]; P = .27). There were no significant between-treatment phase differences in daily activity levels (5497 vs 5503 accelerometry units; difference, -15 [95% CI, -264 to 234]; P = .91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 vs 61.9; difference, 1.1 [95% CI, -1.4 to 3.5]; P = .39), functional class (2.5 vs 2.5; difference, 0.1 [95% CI, -0.1 to 0.2]; P = .43), echocardiographic E/e' ratio (16.4 vs 16.6; difference, 0.1 [95% CI, -1.2 to 1.3]; P = .93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 vs 533 pg/mL; difference, 11 [95% CI, -53 to 75]; P = .74). Worsening heart failure occurred in 3 participants (2.9%) during the nitrite phase and 8 (7.6%) during the placebo phase. CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02742129.
引用
- Borlaug BA, Anstrom KJ, Lewis GD, et al. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. JAMA. 2018. PMID: 30398602. doi:10.1001/jama.2018.14852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。